Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study

Condition:   BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer Intervention:   Drug: Olaparib tablets Sponsor:   National Cancer Institute, Naples Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

BOSTON (CBS) – Not only do IUDs prevent pregnancy, they may lower the risk of ovarian cancer in the women who use them. Researchers at the University of Colorado reviewed a dozen prior studies involving several thousand patients and found that women who used IUDs were up to 32-percent less likely than other women to develop ovarian cancer. It’s not clear why, but scientists found that the hormones released by some IUDs may block estrogen which help ovarian tumor glow. And having a foreign body in the uterus may trigger the immune system to help fight cancer. Birth control pills have also been linked to a lower ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health Healthwatch News Syndicated CBSN Boston Syndicated Local Dr. Mallika Marshall IUD ovarian cancer Source Type: news
Publication date: Available online 16 October 2019Source: Academic RadiologyAuthor(s): He An, Keith W.H. Chiu, K.Y. Tse, Hextan Y.S. Ngan, Pek-Lan Khong, Elaine Y.P. LeeRationale and ObjectivesTo evaluate the diagnostic performance of contrast-enhanced computed tomography (CT) in predicting residual disease following neo-adjuvant chemotherapy (NACT) in stage III/IV ovarian cancer.Materials and MethodsThis was a retrospective observational cohort study including consecutive patients with primary stage III/IV ovarian cancer who received NACT before interval debulking surgery. CT findings before interval debulking surgerywere...
Source: Academic Radiology - Category: Radiology Source Type: research
Doctors at the Swiss Group for Clinical Cancer Research in Zurich, Switzerland, have uncovered a novel, anti-tumor compound that could become a needed second-line treatment for pleural mesothelioma cancer. Their recent multicenter phase II clinical trial conducted in Switzerland and Italy revealed the safety and efficacy of lurbinectedin, a synthetically produced agent that inhibits the growth of mesothelioma cells. “We believe this could represent a new treatment option for pleural mesothelioma,” Dr. Yannis Metaxas, oncologist at Kantonsspital Graubunden outside Zurich, told The Mesothelioma Center at Asbestos...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conclusion: Our data suggest that RNA in pelvic mass samples is relatively stable. Knowledge about RNA stability is an important prerequisite for research in RNA biomarkers, where the challenge is to balance the need for careful RNA handling and storage with the need for effective large-scale biobanking in a busy clinical setting where patient treatment is the main priority. PMID: 31618057 [PubMed - as supplied by publisher]
Source: Biopreservation and Biobanking - Category: Biomedical Science Tags: Biopreserv Biobank Source Type: research
Publication date: Available online 16 October 2019Source: Saudi Pharmaceutical JournalAuthor(s): Moureq Rashed Alotaibi, Homood Moqbel As Sobeai, Faten Abdullah Alaqil, Mashal Almutairi, Khalid Alhazzani, Adam A.A. Sulaiman, Anvarhusein A. Isab, Nasser Hadal AlotaibiAbstractthere are many mechanisms of resistance, chemoresistance of HeLa cells to anti-cancer agents seems to be autophagy-mediated. While using very effective anti-cancers such as Doxorubicin and cisplatin, cells overcome the cytotoxicity of these drugs through promotion of what so-called cytoprotective autophagy. Here in this study, we sought to introduce a n...
Source: Saudi Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
ConclusionOur data suggest that miR-133a-3p/PYGB/Wnt-β-catenin axis plays a critical role in human ovarian cancer, which might serve as a promising therapeutic target of ovarian cancer treatment in the future.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
AbstractPARP (poly(ADP-ribose) polymerase) inhibitors represent a novel class of anti-cancer therapy; they take advantage of synthetic lethality and induce cell death by exploiting a defect in DNA repair. This class of medication was initially evaluated in patients with BRCA-associated tumors, but efficacy was also demonstrated in other populations. Since 2014, four PARP inhibitors have been approved in various indications: olaparib, niraparib, and rucaparib in high-grade serous ovarian cancer, and olaparib and talazoparib in metastatic breast cancer. The exact indications and study populations vary slightly between the di...
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
Giorgia Mangili The majority of patients with advanced ovarian germ cell cancer are treated by cisplatin-based chemotherapy. Despite adequate first-line treatment, nearly one third of patients relapse and almost half develop cisplatin-resistant disease, which is often fatal. The treatment of cisplatin-resistant disease is challenging and prognosis remains poor. There are limited data on the efficacy of specific chemotherapeutic regimens, high-dose chemotherapy with autologous progenitor cell support and targeted therapies. The inclusion of patients in clinical trials is strongly recommended, especially in clinical tria...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
(Reuters Health) - Women who use intrauterine devices (IUDs) for birth control may be less likely to develop ovarian cancer, a research review suggests.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
ConclusionsAs a new tumor marker, HE4 shows high specificity and efficacy in the Chinese population, while the ROMA that combines HE4 and CA 125 shows high sensitivity and a high Youden’s index. These markers should be extended to China since they have good diagnostic performances.
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Ovarian Cancer | Ovaries | Research | Study